 Shriram Finance Ltd Q2FY26 consolidated PAT increases to Rs. 2314.17 crores
Shriram Finance Ltd Q2FY26 consolidated PAT increases to Rs. 2314.17 crores GAIL India Ltd reports consolidated PAT of Rs. 1972.40 crores in Q2 FY26
GAIL India Ltd reports consolidated PAT of Rs. 1972.40 crores in Q2 FY26 The Phosphate Company Ltd Q2FY26 loss at Rs. 2.48 crore
The Phosphate Company Ltd Q2FY26 loss at Rs. 2.48 crore Emami Paper Mills Ltd Q2 FY2026 profit at Rs. 6.58 crores
Emami Paper Mills Ltd Q2 FY2026 profit at Rs. 6.58 crores Maruti Suzuki India Ltd Q2 FY2026 consolidated PAT slips QoQ to Rs. 3349 crores
Maruti Suzuki India Ltd Q2 FY2026 consolidated PAT slips QoQ to Rs. 3349 crores 
              The trustees of Reliance Mutual Fund have approved August 28, 2009 as the record date for declaration of 15% dividend under Reliance Pharma Fund.
Accordingly dividend will be paid to all the unitholders whose names appear on the Register of investors/unitholders of the schemes, on August 28, 2009 subject to availability of distributable surplus under the scheme.
The Face Value of Mutual Fund units are Rs 10 and the dividend declared is 15% or Rs 1.50 per unit.
The NAV (Net Asset Value) of Reliance Pharma Fund was Rs 24.1308 on August 20, 2009. It should be noted that pursuant to payment of dividend, the NAV of the scheme would fall to the extent of dividend payout and statutory levy if any.
Past performance may or may not be sustained in the future and should not be used as a basis of comparison with other investments.
Mutual Funds and Securities Investments are subject to market risks and there is no assurance or guarantee that the objectives of the scheme will be achieved. Please read the scheme information documents / addendums of the schemes carefully before investing.